Crossover RPSFT — SCE Medical Oncology MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: E — Crossover diluted the OS benefit; RPSFT/IPCW adjustment estimates the true treatment effect had crossover not occurred — NICE considers adjusted analyses when ITT OS is confounded
Crossover gives control patients the experimental drug, diluting ITT OS difference. RPSFT/IPCW methods estimate counterfactual OS. NICE explicitly considers these in technology appraisals.
Reference: JRCPTB; NICE Methods Guide; Latimer et al Med Decis Making 2014